RxDoctor Payments Data

Milind Karve, MD

Cardiovascular Disease · Lansing, MINPI 1285609537

Payments from drug & device makers

$27,417in general payments, 2019–2025

Across 693 payments — averaging $39.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$4K
  • AstraZeneca$4K
  • Angiodynamics, Inc.$3K
  • Shockwave Medical, Inc$2K
  • Abiomed$1K
  • plus $10K from 47 others

What the payments were for

  • Consulting fees$6302%
  • Speaking & faculty fees$3,00011%
  • Travel & lodging$4,99618%
  • Food & beverage$18,72568%
  • Education$660%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,417 in reported general payments places this provider in the 80th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$350,779
Medicare patients
513
Services billed
4,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban229$286,703
XareltoRivaroxaban84$104,664
EntrestoSacubitril/Valsartan64$81,431
FarxigaDapagliflozin Propanediol51$56,776
JardianceEmpagliflozin38$51,991
BrilintaTicagrelor47$44,697
MultaqDronedarone Hcl16$30,474
Repatha SureclickEvolocumab16$16,612
Icosapent Ethyl13$6,584
Dofetilide26$5,338
Metoprolol Succinate312$5,245
Atorvastatin Calcium290$4,715
Ezetimibe107$4,369
ClopidogrelClopidogrel Bisulfate147$3,631
Isosorbide Mononitrate ErIsosorbide Mononitrate142$3,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$591$286,703229 claims
Johnson & JohnsonXarelto$611$104,66484 claims
AstraZenecaFarxiga, Brilinta$3,510$101,47398 claims
NovartisEntresto$1,381$81,43164 claims
Boehringer IngelheimJardiance$1,404$51,99138 claims
Sanofi-aventis U.S. LLCMultaq$174$30,47416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →